Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 13/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21451834 | 0.85 | CDK4 (0.40) | CDK4CDK2CDK6PDCD1CD274 | |
| SCHEMBL18806181 | 0.80 | CDK4 (0.40) | CDK4CDK2CDK6PDCD1CD274 | |
| SCHEMBL20255390 | 0.77 | CDK4 (0.43) | CDK4CDK2CDK6PDCD1CD274 | |
| SCHEMBL20249376 | 0.77 | PDCD1 (0.47) | CDK4CDK2CDK6PDCD1CD274 | |
| SCHEMBL18806155 | 0.75 | CDK4 (0.44) | CDK4CDK2CDK6LMNA | |
| SCHEMBL22966562 | 0.75 | CD274 (0.51) | CDK4CDK2CDK6PDCD1CD274 | |
| SCHEMBL22966559 | 0.75 | CDK4 (0.42) | CDK4CDK2CDK6MAPTLMNA | |
| SCHEMBL20249391 | 0.75 | CDK4 (0.42) | CDK4CDK2CDK6 | |
| SCHEMBL18819904 | 0.75 | CDK4 (0.41) | CDK4PDCD1CD274MAPTLMNA | |
| SCHEMBL18806194 | 0.75 | ADORA2A (0.37) | CDK4CDK2CDK6PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | CDK4 2354/4885CDK2 2975/4885CDK6 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.